CFO of Plus Therapeutics Buys Zero‑Cost RSUs and Options, Betting on Reimbursement Boosts

Insider Activity Spotlight: Plus Therapeutics’ CFO Buys Restricted Shares and Options

On February 25 2026, Chief Financial Officer Andrew MacIntyre purchased 349,542 Restricted Stock Units (RSUs) and an equal number of Stock Options, each vesting over a twelve‑quarter period beginning April 2026. The transaction is priced at zero because the units are contingent on future performance; they effectively represent a long‑term equity incentive rather than a cash purchase. In a company where the share price is hovering around $0.28, the CFO’s move signals confidence in the company’s trajectory and a desire to align his interests with shareholders.

Implications for Investors and Company Momentum

MacIntyre’s buy order comes amid a 16.5 % monthly gain and a 8.2 % weekly upside, yet the broader market remains cautious with a 55 % year‑to‑date decline. The CFO’s commitment suggests that the senior management believes the recent CPT‑code expansion for REYOBIQ™ will unlock new reimbursement channels, potentially improving revenue streams. For investors, this could mean that the stock’s current low valuation—pegged at a price‑to‑earnings ratio of –0.6—may be a discount relative to future earnings potential. However, the high volatility (52‑week high of $2.31 vs. low of $0.16) cautions against treating this as a guaranteed upside.

What This Means for Plus Therapeutics’ Future

The CFO’s simultaneous purchase of RSUs and options indicates a two‑tier strategy: a steady, vesting‑based stake that rewards long‑term performance, and an option position that allows participation in a sharp upside if the company’s clinical milestones or reimbursement approvals accelerate. The timing—right after a corporate announcement—suggests that insiders are betting on short‑term catalysts. If the company secures broader payer coverage, the share price could rally, benefiting those holding options and RSUs alike. Conversely, if clinical results fall short, the value of these incentives may dry up, leaving the stock exposed to the same volatility that has plagued it throughout 2025.

Profile of CFO Andrew MacIntyre

MacIntyre’s insider trading history reveals a pattern of buying and selling in large blocks, often around pivotal corporate events. In October 2025 he sold 38,323 RSUs while simultaneously buying 38,323 common shares, then in August 2025 he accumulated 459,878 RSUs and 1,379,636 stock options. These moves align with the company’s development milestones and funding rounds, indicating a strategy that balances immediate liquidity needs with long‑term equity exposure. His recent February purchase of 349,542 RSUs and an equal number of options suggests that he views the current market dip as a buying opportunity, reinforcing his belief in Plus Therapeutics’ long‑term value.

Takeaway for Investors

For those weighing an investment in Plus Therapeutics, the CFO’s recent purchases should be viewed as a bullish signal tempered by the company’s volatile history and negative earnings. The alignment of executive equity with shareholders is encouraging, yet the reliance on contingent units and options underscores that the upside is still contingent on regulatory and clinical success. Investors should monitor the company’s clinical trial progress and reimbursement negotiations closely—these will be the key drivers that determine whether MacIntyre’s insider confidence translates into a sustained price rally.